Optimizing the Pharmacokinetics of Sonidegib in Small Bowel Syndrome and Advanced Basal Cell Carcinoma: Our Solution

Main Article Content

Hailey Grubbs
Dermatology Department, Broward Health Medical Center

Marianne Cortes
Nova Southeastern University Kiran C Patel College of Osteopathic Medicine

John Strasswimmer
Florida Atlantic University; Strasswimmer Mohs Surgery

Keywords

sonidegib, vismodegib, advanced basal cell carcinoma, basal cell carcinoma, Hedgehog pathway inhibitor, skin cancer, dosing strategies, alternate dosing, comorbidities, intestinal malabsorption, dysphagia, treatment, pharmacokinetics, cutaneous oncology, oncology

References

1. Asgari MM, et al. JAMA Dermatol. 2015;151(9):976–81.

2. Marzuka AG, Book SE. Yale J Biol Med. 2015;88:167–79.

3. Amici JM, et al. Eur J Dermatol. 2015;25(6):586–94.

4. Kim JYS, et al. J Am Acad Dermatol. 2018;78(3):540–59.

5. Cortes JE, et al. Cancer Treat Rev. 2019;76:41–50.

6. Jain S, et al. OncoTargets Ther. 2017;10:1645–53.

7. ODOMZO® (sonidegib capsules). Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA. 2019.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.182

Article Details

How to Cite
[1]
Grubbs, H., Cortes, M. and Strasswimmer, J. 2023. Optimizing the Pharmacokinetics of Sonidegib in Small Bowel Syndrome and Advanced Basal Cell Carcinoma: Our Solution. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s182. DOI:https://doi.org/10.25251/skin.7.supp.182.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)